BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12539213)

  • 1. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B; Johnels B; Blennow K; Rosengren L
    Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
    Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
    J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid Abeta42 levels in multiple system atrophy.
    Verbeek MM; Abdo WF; De Jong D; Horstink MW; Kremer BP; Bloem BR
    Mov Disord; 2004 Feb; 19(2):238-40; author reply 240-1. PubMed ID: 14978688
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
    Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
    Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
    Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
    Paviour DC; Thornton JS; Lees AJ; Jäger HR
    Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.
    Schulz JB; Skalej M; Wedekind D; Luft AR; Abele M; Voigt K; Dichgans J; Klockgether T
    Ann Neurol; 1999 Jan; 45(1):65-74. PubMed ID: 9894879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Ashour R; Jankovic J
    Mov Disord; 2006 Nov; 21(11):1856-63. PubMed ID: 16941460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
    Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
    Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Bukhatwa S; Zeng BY; Rose S; Jenner P
    Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
    Juh R; Kim J; Moon D; Choe B; Suh T
    Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.